What is the formulation of Trelegy (fluticasone furoate/umeclidinium/vilanterol) inhaler?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Trelegy Formulation

Trelegy Ellipta is a once-daily, single-inhaler triple therapy delivered as a dry powder inhaler containing fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta-2 agonist). 1

Device and Delivery System

The medication is delivered through the ELLIPTA inhaler, a light grey and beige plastic device containing 2 separate foil blister strips 1:

  • First blister strip: Contains micronized fluticasone furoate (100 or 200 mcg) mixed with lactose monohydrate
  • Second blister strip: Contains micronized umeclidinium bromide (74.2 mcg equivalent to 62.5 mcg umeclidinium) and micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg vilanterol), plus magnesium stearate and lactose monohydrate

When activated, both blisters simultaneously expose their powder contents for inhalation through the mouthpiece 1.

Available Strengths

Two formulations are available 1:

  • FF/UMEC/VI 100/62.5/25 mcg (approved for COPD and asthma)
  • FF/UMEC/VI 200/62.5/25 mcg (approved for asthma)

Actual Delivered Dose

Under standardized testing conditions at 60 L/min flow rate, the inhaler delivers 1:

  • 92 or 184 mcg of fluticasone furoate
  • 55 mcg of umeclidinium
  • 22 mcg of vilanterol

The device maintains ≥90% of target dose delivery across flow rates of 30-90 L/min, making it effective even in patients with severe airflow limitation 1.

Clinical Context

This single-inhaler formulation represents an advancement over multiple-inhaler regimens, as it combines all three medication classes in one device with once-daily dosing 2. The ELLIPTA device has demonstrated good adherence and patient preference in real-world studies 3, with mean peak inspiratory flows of 65.8 L/min in very severe COPD patients and 96.6 L/min in severe asthma patients 1.

Important caveat: The lactose monohydrate excipient contains milk proteins, which is relevant for patients with severe milk protein allergy 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.